Starting with the first outstanding results of the anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody, Ipilimumab, in melanoma [1] and following use of antibodies against programmed cell death protein 1 (PD-1) and its ligand PD-L1 (nivolumab, pembrolizumab, atezolizumab) in non-small cell lung cancer (NSCLC) [2,3,4,5], immunotherapy with checkpoint inhibitors has gradually changed the management of malignant tumors by improving the long term benefit and survival. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.